Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
about
P1343
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signalingIdentification of semaphorin E as a non-MDR drug resistance gene of human cancersNano-mechanical Phenotype as a Promising Biomarker to Evaluate Cancer Development, Progression, and Anti-cancer Drug EfficacyChemoresistance and targeted therapies in ovarian and endometrial cancersβ-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cellsComparative analysis of different methodological approaches to the in vitro study of drug-induced apoptosisCisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study.Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells.Targeting mitochondrial DNA with a platinum-based anticancer agent.Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation.Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug.Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancerAn ERCC1 splicing variant involving the 5'-UTR of the mRNA may have a transcriptional modulatory function.Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsGlutathione and drug resistance.Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsCisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitroA metabolomic approach to identifying platinum resistance in ovarian cancer.MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines.Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.Rapid gene-specific repair of cisplatin lesions at the human DUG/DHFR locus comprising the divergent upstream gene and dihydrofolate reductase gene during early G1 phase of the cell cycle assayed by using the exonucleolytic activity of T4 DNA polymeSodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesMechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.Complex cisplatin-double strand break (DSB) lesions directly impair cellular non-homologous end-joining (NHEJ) independent of downstream damage response (DDR) pathwaysAssociation of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian CancerNucleotide excision repair and anti-cancer chemotherapyGlutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatinIncreased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells
P2860
Q21131951-D786FED7-455B-4365-BA20-0BDEC764E382Q24315145-C5644F33-6BB8-4E06-8492-EF5C83D94100Q26743450-5B2C18B5-0713-4D18-B118-D273A5A8F3EAQ28073246-4BE601F4-9975-427D-9DE4-1D090756BC48Q28387031-8CA598FE-6690-44CB-A46D-ADEC93B0A3BEQ33178991-0DFC8AB2-056A-4029-B5FF-5DA66249FDA8Q33330720-E8835CFE-6473-4516-8160-09F2338D5B06Q33334489-E02D4114-9BDF-486E-A380-BE245109A92FQ33503243-C8E1B4EB-7D2A-4A76-AAEF-D2A912125D02Q33764106-D24F7C96-56B5-4ABB-9A5D-AF0B56F31B76Q33847450-A5F88580-8671-42A2-8A70-4020CFAE1964Q33873995-9777B756-59B8-44C4-B2A8-9FC09F5DE184Q33881681-63D225B7-F416-4406-A0E4-40681B087EB9Q34024735-6336F98D-3836-4ECD-8563-CBE35431A1E3Q34106291-F1CA8546-5187-4CC5-A3A3-DB1BF9B7E2E9Q34142384-9BE76E9C-E0AF-4097-B220-7680D4D79141Q34229177-0AE9D75E-59B6-4AA2-A023-4916F0A8B286Q34328748-1A4B905F-401C-4E49-B417-D1F19162C28CQ34374824-5A61DA93-48F5-44EA-B3CC-2530B0BC2E76Q34722650-30384E05-247D-4856-A62F-2EE0017AC321Q34843715-78F75DD0-F3CE-4CF5-8A93-FBF552BB64B6Q35404082-9513E9F8-A22D-423D-B5A9-18EDC35AEA54Q35487297-2DE7F298-24BD-4669-A5B0-ACAB5BBFB64DQ35709343-693BD8A2-FD3B-4D0C-93B7-0FF6631AC651Q35888670-DBCCE60E-78C3-474C-82BE-9E878724696BQ35892810-7F9162D3-17CD-49DC-8993-2BE23BA7746AQ35978030-218F5816-D228-428F-8A96-166C5DBA8807Q35997145-D33C51D9-B1F8-4019-9CB5-78ECE030C6E0Q36097945-893ED671-C1D2-453C-9EEB-062D0E70D24CQ36119145-25F9264E-7BD7-4C3A-9F45-135F8C5E8487Q36176287-AFB14CAE-DF10-40DA-8430-D4958F76E5E0Q36254803-FFB774AC-B309-4FB4-B33D-EDBC10A33C5CQ36291188-E55A265A-8D38-4AFE-87C9-6DDE580DE897Q36296744-87BEEDF6-241A-4602-A5A0-EF6F31FCBEAEQ36414274-212C4429-4266-47B7-B5A8-56B8C207A092Q36415308-8B409F9C-402E-42C4-9ED8-A510375519D5Q36617626-6BB4F390-F6F7-41CF-8D4B-9E1706026119Q36698590-13CD3A2B-BD90-464D-9525-A2C02D653AD7Q36816030-E7F27AD4-1495-4D42-91C0-574390DDD82FQ36985163-DE3830A2-8D94-4665-BF9B-F71A399701AF
P2860
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Acquired cisplatin resistance ...... and reduced drug accumulation.
@ast
Acquired cisplatin resistance ...... and reduced drug accumulation.
@en
type
label
Acquired cisplatin resistance ...... and reduced drug accumulation.
@ast
Acquired cisplatin resistance ...... and reduced drug accumulation.
@en
prefLabel
Acquired cisplatin resistance ...... and reduced drug accumulation.
@ast
Acquired cisplatin resistance ...... and reduced drug accumulation.
@en
P2093
P2860
P356
P1476
Acquired cisplatin resistance ...... and reduced drug accumulation.
@en
P2093
Bostick-Bruton F
P2860
P304
P356
10.1172/JCI115080
P407
P4510
P577
1991-03-01T00:00:00Z